Amgen Trials For Manufacturing Changes Touted As Model For Bio-Generics
Executive Summary
Amgen is highlighting large-scale trials it is conducting for products that have undergone manufacturing process changes in the debate over approval requirements for follow-on biologics
You may also be interested in...
FDA Sees Critical Path Opportunity To Address Follow-On Biologics
FDA's Critical Path opportunities list suggests that the agency is actively working to lay the scientific groundwork for follow-on biologics
FDA Sees Critical Path Opportunity To Address Follow-On Biologics
FDA's Critical Path opportunities list suggests that the agency is actively working to lay the scientific groundwork for follow-on biologics
Follow-On Protein 505(b)(2) Applications Do Not Require Pharm/Tox Studies
Follow-on protein applications submitted under the 505(b)(2) mechanism do not require pharmacology/ toxicology studies, Office of Clinical Pharmacology & Biopharmaceutics Team Leader Hae-Young Ahn said Feb. 14